A prescribing decision is usually described as a moment. It is more accurately a sequence, one that runs across three separate people, over hours or weeks, most of which no single vendor can see.
Understanding it as a sequence rather than a point changes what you buy, what you measure, and where you look when the numbers don’t move.
That fragmentation is why we launched Care Sequence, powered by Clinical Intent Signals.
Care Sequence is designed to connect one patient encounter from the waiting room and consultation through the prescription, follow-up, patient portal, pharmacy, fill and refill.
It reaches the patient, physician and pharmacist on the same verified clinical context rather than treating each touchpoint as a separate media buy. Clinical Intent Signals bring together context across diagnosis, clinical workflow, prescribing, therapy changes, access, affordability, fulfilment and refill behaviour, enabling activation at the source of the decision and measurement through prescribing outcomes.
That does not mean every moment should carry the same message. It means each moment can respond to what has just happened and what needs to happen next - planned as one care sequence rather than a collection of disconnected placements. Below are the moments that make up this connected care sequence.
The patient arrives already thinking about their condition. They are minutes away from a conversation about it with someone they trust, and they have nothing else to do.
There is almost no other point in a patient’s life where attention and relevance align that precisely. Most waiting-room media is bought by location, the practice treats a lot of relevant patients, so you buy the practice.
That is a reasonable proxy. It is also why patients visiting for something unrelated see messages about conditions they do not have.
The physician opens the chart and works through the encounter — patient intake, diagnostic ordering, diagnosis review and entry, medication review and prescribing.
Being in the EHR is not the same as being in the workflow. A message in a frame adjacent to the chart is near the clinical work; a message rendered at a workflow step is part of it.
Both exist, network policies differ on which is permitted, and any vendor claiming in-workflow delivery should be able to name the specific steps.
Something specific comes up - dosing in renal impairment, an interaction or a first-line choice for an atypical presentation. The physician asks.
Increasingly, they ask an AI assistant inside the EHR without leaving the chart.
That is a genuinely different kind of interaction: not an impression waiting to be noticed, but an active question asked at the exact point of deciding, with the patient in the room.
It is also the point that raises the most legitimate questions about where promotional content belongs. It deserves to be handled carefully rather than opportunistically.
This is the prescribing decision itself, and the part of the sequence the industry has optimised hardest.
The distinction that matters here is between targeting a likely prescriber and acting on a verified clinical event.
The first is a probabilistic guess about timing. The second activates when a verified ICD-10, CPT or NDC signal is actually present — establishing clinical relevance before anything serves.
But the script is not the outcome. It is the hand-off to the next stage of care.
The decision carries beyond the encounter and into what happens next.
A message keyed to the specific clinical action just taken, delivered to a verified NPI while the context is still fresh, behaves differently from a scheduled email in a nurture flow.
The difference is not simply timing. It is the connection between the communication and the verified action that preceded it.
The patient goes home and decides whether to actually fill the prescription.
This is where most journey maps become vague and most media plans go quiet.
The patient portal - where patients read the doctor’s note, pay for medication, check a result or schedule a refill - is one of the few contexts where they are actively managing their care rather than being interrupted while doing something else.
The message at this stage may need to address a completely different barrier from the message delivered before or during the consultation. The patient may now be thinking about access, affordability, side effects, administration or whether treatment is necessary at all.
Reaching the patient again only matters when the communication reflects that change in context.
A pharmacist processes the prescription in a pharmacy management system. They see the NDC, the coverage type and what the patient will actually pay.
At that point, the pharmacist is the only party in the sequence with both the information and the relationship needed to change the outcome.
A prescription may be clinically appropriate and still fail because of cost, coverage, availability or patient hesitation. The pharmacist is often the person best placed to explain an alternative, identify an affordability option or help the patient understand the next step.
The same principle applies at refill. Initiating therapy is not the same as remaining on it, and a connected sequence should be able to distinguish between the two.
The two things a connected care sequence has that disconnected placements don’t.
Almost every vendor in healthcare media can reach a patient somewhere — in the room, at check-in, in a portal or across the open web.
Very few can reach the same patient before the visit, after it and again at the pharmacy counter, connected through one identity.
The distinction matters because the patient who abandons a prescription at the counter may be the same patient a brand paid to engage weeks earlier. When those interactions are bought separately, nothing in the reporting connects the two facts.
Buying individual patient touchpoints and carrying a patient through a care sequence are different products.
When the waiting room comes from one company, the EHR from another, email from a third and the portal from a fourth, none of them can see the complete encounter.
When prescriptions do not convert, each vendor can still report that its own placement delivered. No single party sees where the sequence broke, and no single party can be held accountable for improving it.
A connected sequence changes that. It allows performance to be assessed across the path from clinical intent to prescription, access, fill and refill - rather than measuring each placement in isolation.
Take your current plan and map it across all moments of care.
Mark where you are present, where you are partially present and where you are absent.
Most brands find they are strongest around the prescription itself, thinner before and after it, and largely absent at the points where access, affordability and follow-through determine whether the prescription becomes therapy.
That exercise is more useful than any vendor deck, including ours.
Doceree’s Care Sequence, powered by Clinical Intent Signals, connects all moments of care through one verified clinical context -reaching the patient, physician and pharmacist from the waiting room through fill and refill.